Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3466769 | 1.00 | GABRA1 (0.45) | GABRA1GABRG2GABRB3TDP1GSK3B | |
| SCHEMBL3466020 | 0.92 | GABRA1 (0.42) | GABRA1GABRG2GABRB3TDP1GSK3B | |
| SCHEMBL3466019 | 0.92 | GABRA1 (0.42) | GABRA1GABRG2GABRB3TDP1GSK3B | |
| SCHEMBL3465868 | 0.91 | GABRA1 (0.41) | GABRA1GABRG2GABRB3TDP1GSK3B | |
| SCHEMBL3465871 | 0.91 | GABRA1 (0.41) | GABRA1GABRG2GABRB3TDP1GSK3B | |
| SCHEMBL3467387 | 0.90 | PDPK1 (0.45) | GABRA1GABRG2GABRB3TDP1MAPT | |
| SCHEMBL3467390 | 0.90 | PDPK1 (0.45) | GABRA1GABRG2GABRB3TDP1MAPT | |
| SCHEMBL3465809 | 0.88 | GSK3B (0.38) | GABRA1GABRG2GABRB3TDP1GSK3B | |
| SCHEMBL3465810 | 0.88 | GSK3B (0.38) | GABRA1GABRG2GABRB3TDP1GSK3B | |
| SCHEMBL3466511 | 0.87 | GABRA1 (0.41) | GABRA1GABRG2GABRB3TDP1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273651-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | BASF SE (DE) | 2010-10-28 | — | — | US | disclosed |
| EP-2235005-A2 | AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009077500-A2 | AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2009-06-25 | — | — | WO | disclosed |
| EP-0196583-B1 | USE OF AZOLYL METHYL OXIRANES TO COMBAT VIRAL DISEASES | BASF Aktiengesellschaft (DE) | 1991-10-23 | — | — | EP | disclosed |
| EP-0094564-B1 | AZOLYL-METHYL OXIRANES, THEIR PREPARATION AND USE AS MEDICAMENTS AND PLANT PROTECTING AGENTS | BASF Aktiengesellschaft (DE) | 1987-09-30 | — | — | EP | disclosed |
| US-4652580-A | Application of azolylmethyloxiranes for the treatment of viral diseases | BASF AKTIENGESELLSCHAFT (DE) | 1987-03-24 | — | — | US | disclosed |
| EP-0196583-A2 | Use of azolyl methyl oxiranes to combat viral diseases | BASF Aktiengesellschaft (DE) | 1986-10-08 | — | — | EP | disclosed |
| US-4464381-A | Fungicides containing azolylmethyloxiranes | BASF AKTIENGESELLSCHAFT (DE) | 1984-08-07 | — | — | US | disclosed |
| EP-0094564-A2 | Azolyl-methyl oxiranes, their preparation and use as medicaments and plant protecting agents | BASF Aktiengesellschaft (DE) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273651-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | XDH, SQOR, NOX5 | GABRA1 349/4885GABRG2 506/4885GABRB3 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.